315 reports of this reaction
3.2% of all MIDODRINE HYDROCHLORIDE reports
#3 most reported adverse reaction
DYSPNOEA is the #3 most commonly reported adverse reaction for MIDODRINE HYDROCHLORIDE, manufactured by Advagen Pharma Limited. There are 315 FDA adverse event reports linking MIDODRINE HYDROCHLORIDE to DYSPNOEA. This represents approximately 3.2% of all 9,858 adverse event reports for this drug.
Patients taking MIDODRINE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among MIDODRINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for MIDODRINE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 315 FDA reports for MIDODRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.2% of all adverse event reports for MIDODRINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking MIDODRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.